Portal vein embolization for liver regeneration followed by staged hepatectomy for cholangiocarcinoma
Record ID 32011001495
English
Authors' objectives:
Cholangiocarcinoma (CCA) is a primary malignant tumor originating from epithelial cells lining the intra- and extrahepatic biliary trees. Common to the majority of patients with CCA is the finding of advanced disease at presentation. CCAs are usually slow growing, cause bile duct obstruction, and
do not metastasize early. They affect both men and women, with most patients > 65 years of age. CCA is a relatively rare cancer, with an annual incidence of 1 to 2 cases per 100,000 in the Western world. There is no potentially curative treatment for CCA except radical surgery (hepatectomy). Outcomes after major hepatic resection are linked to volume and function of the portion of the liver that will remain after resection, which is known as the future liver remnant (FLR). Patients without underlying liver disease will tolerate resection of 60% to 70% (FLR, 40% to 30%) of the total liver volume (TLV) without a significant increase of postoperative hepatic failure. In patients with diseased livers this percentage is lower. Lack of adequate FLR may be the primary obstacle to curative resection for a subset of patients. Portal vein embolization (PVE) is a presurgical treatment for patients in anticipation of extensive liver resection with a small FLR volume. PVE is used to increase the volume and function of the FLR before resection. PVE redirects portal blood flow to the intended liver remnant to induce hypertrophy of the nondiseased portion of the liver. The increase in FLR volume following PVE correlates with increased function of the FLR. Liver regeneration usually peaks within the first 2 weeks after PVE.
do not metastasize early. They affect both men and women, with most patients > 65 years of age. CCA is a relatively rare cancer, with an annual incidence of 1 to 2 cases per 100,000 in the Western world. There is no potentially curative treatment for CCA except radical surgery (hepatectomy). Outcomes after major hepatic resection are linked to volume and function of the portion of the liver that will remain after resection, which is known as the future liver remnant (FLR). Patients without underlying liver disease will tolerate resection of 60% to 70% (FLR, 40% to 30%) of the total liver volume (TLV) without a significant increase of postoperative hepatic failure. In patients with diseased livers this percentage is lower. Lack of adequate FLR may be the primary obstacle to curative resection for a subset of patients. Portal vein embolization (PVE) is a presurgical treatment for patients in anticipation of extensive liver resection with a small FLR volume. PVE is used to increase the volume and function of the FLR before resection. PVE redirects portal blood flow to the intended liver remnant to induce hypertrophy of the nondiseased portion of the liver. The increase in FLR volume following PVE correlates with increased function of the FLR. Liver regeneration usually peaks within the first 2 weeks after PVE.
Details
Project Status:
Completed
Year Published:
2011
URL for published report:
http://www.hayesinc.com/hayes/crd/?crd=12918
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Cholangiocarcinoma
- Embolization, Therapeutic
- Liver Regeneration
- Portal Vein
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
2011 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.